AIM: To determine whether hyperuricemia is associated with the early phase and late phase of insulin release in apparently healthy non-obese subjects with normal glucose tolerance. MATERIALS AND METHODS: A population-based cross-sectional study was performed. Apparently healthy individuals aged 20 to 65 years were eligible to participate. Smoking, alcohol intake ≥30 g per day, obesity, glomerulopathies, hepatic disease, malignancy, cardiovascular disease, and medical treatment in the last 3 months, were exclusion criteria. Hyperuricemia was defined by fasting uric acid levels ≥6 mg/dL and ≥7 mg/dL for women and men, respectively. Insulin release was evaluated by estimating the early and late phases of insulin release. The association between hyperuricemia (independent variables) and insulin release (dependent variables) was estimated using multiple linear regression analysis. RESULTS: A total of 123 subjects, without significant differences in age (32.4 ± 12.8 and 34.7 ± 9.9 y), body mass index (25.3 ± 3.7 and 24.7 ± 3.0 kg/m2), and waist circumference (94.6 ± 9.7 and 90.2 ± 9.3 cm), were allocated into the groups with (n = 25) and without (n = 98) hyperuricemia. The linear regression model, adjusted by HOMA-IR and triglyceride levels, showed a significant association of hyperuricemia with both the early phase (B = 508.8; 95%CI 253.3-764.4, p<0.001) and late phase of insulin release (B = 35.0; 95%CI 8.7-61.3, p = 0.009). CONCLUSIONS: Hyperuricemia is associated with the increase of early and late phases of insulin release in apparently healthy non-obese subjects with normal glucose tolerance.
AIM: To determine whether hyperuricemia is associated with the early phase and late phase of insulin release in apparently healthy non-obese subjects with normal glucose tolerance. MATERIALS AND METHODS: A population-based cross-sectional study was performed. Apparently healthy individuals aged 20 to 65 years were eligible to participate. Smoking, alcohol intake ≥30 g per day, obesity, glomerulopathies, hepatic disease, malignancy, cardiovascular disease, and medical treatment in the last 3 months, were exclusion criteria. Hyperuricemia was defined by fasting uric acid levels ≥6 mg/dL and ≥7 mg/dL for women and men, respectively. Insulin release was evaluated by estimating the early and late phases of insulin release. The association between hyperuricemia (independent variables) and insulin release (dependent variables) was estimated using multiple linear regression analysis. RESULTS: A total of 123 subjects, without significant differences in age (32.4 ± 12.8 and 34.7 ± 9.9 y), body mass index (25.3 ± 3.7 and 24.7 ± 3.0 kg/m2), and waist circumference (94.6 ± 9.7 and 90.2 ± 9.3 cm), were allocated into the groups with (n = 25) and without (n = 98) hyperuricemia. The linear regression model, adjusted by HOMA-IR and triglyceride levels, showed a significant association of hyperuricemia with both the early phase (B = 508.8; 95%CI 253.3-764.4, p<0.001) and late phase of insulin release (B = 35.0; 95%CI 8.7-61.3, p = 0.009). CONCLUSIONS:Hyperuricemia is associated with the increase of early and late phases of insulin release in apparently healthy non-obese subjects with normal glucose tolerance.
Entities:
Keywords:
Hyperuricemia; insulin release; normal glucose tolerance; uric acid
Authors: Cesar I Elizalde-Barrera; Teresa Estrada-García; Jose J Lozano-Nuevo; Ana K Garro-Almendaro; Catalina López-Saucedo; Alberto F Rubio-Guerra Journal: Ther Adv Endocrinol Metab Date: 2017-10-11 Impact factor: 3.565